acetyl coenzyme a has been researched along with Hematologic Malignancies in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Algire, M; Bromberg, KD; Buchanan, FG; Chiang, GG; Choudhary, C; Cole, PA; de Vries, P; Digiammarino, EL; Edalji, RP; Faivre, E; Ferguson, D; Frey, R; Hansen, TM; Hessler, P; Jakob, CG; Karukurichi, K; Kesicki, E; Lai, A; Lam, LT; Langston, JW; Lasko, LM; Manaves, V; Marmorstein, R; Martin, RL; McElligott, D; Michaelides, MR; Montgomery, D; Qiu, W; Risi, RM; Rosenberg, SH; Shaw, B; Sun, C; Torrent, M; Uziel, T; Van Drie, JH; Weinert, BT | 1 |
1 other study(ies) available for acetyl coenzyme a and Hematologic Malignancies
Article | Year |
---|---|
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Topics: Acetyl Coenzyme A; Animals; Antineoplastic Agents; Binding, Competitive; Biocatalysis; Catalytic Domain; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Crystallography, X-Ray; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Histone Acetyltransferases; Humans; Male; Mice; Mice, SCID; Models, Molecular; Neoplasms; p300-CBP Transcription Factors; Prostatic Neoplasms, Castration-Resistant; Protein Conformation; Receptors, Androgen; Xenograft Model Antitumor Assays | 2017 |